Peer-reviewed veterinary case report
Blood test markers miR-216a and miR-375 in dogs
By Lee, Dohee et al.·Published in Journal of veterinary internal medicine·2023·College of Veterinary Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of serum miR-216a and miR-375 as biomarkers in dogs with acute pancreatitis.
- Species:
- dog
Plain-English summary
A group of 21 dogs with acute pancreatitis (AP) had their blood tested for specific microRNAs (miR-216a and miR-375) to see if these could help diagnose the condition and track treatment progress. The results showed that dogs with AP had much higher levels of miR-375 compared to healthy dogs, suggesting it could be a useful marker for the disease. After treatment, the levels of miR-375 decreased significantly, indicating a positive response to therapy. This means that measuring miR-375 could help vets diagnose and monitor dogs with pancreatitis.
People also search for: dog pancreatitis symptoms · dog blood test for pancreatitis · treatment for dog pancreatitis
Abstract
BACKGROUND: Serum microRNAs have emerged as biomarkers of various diseases. Overexpression of serum miR-216a and miR-375 occurs in dogs with experimentally induced acute pancreatitis (AP). OBJECTIVES: To identify the possibility of using serum miR-216a and miR-375 as biomarkers for the diagnosis and evaluation of treatment response in dogs with naturally occurring AP. ANIMALS: Twenty-one dogs with AP and 20 healthy dogs. METHODS: Cross-sectional study. The relative expression of serum hsa-miR-216a-5p, cfa-miR-216a, and cfa-miR-375 were analyzed using reverse transcription and real-time PCR. RESULTS: A significant difference in the serum expression of cfa-miR-375 was found between dogs with AP (median [interquartile range] 3.59 [1.55-24.52]-fold) and healthy dogs (0.81 [0.54-2.21]-fold, P < .001), and no significant differences were observed in hsa-miR-216a-5p and cfa-miR-216a (P > .05). The area under the receiver operating characteristic curve of serum cfa-miR-375 for differentiating between AP dogs and healthy dogs was 0.84 (95% confidence interval [CI]: 0.71-0.96). The expressions of hsa-miR-216a-5p and cfa-miR-375 were positively correlated with the concentrations of serum C-reactive protein (r = .46, r = .48, respectively), but not with the serum specific canine pancreatic lipase. The expression of cfa-miR-375 was significantly less after treatment in dogs with AP (P = .02). CONCLUSIONS AND CLINICAL IMPORTANCE: Serum cfa-miR-375 could be a potential biomarker for the diagnosis and evaluation of treatment response of AP in dogs. In addition, miR-216a and miR-375 could be associated with inflammatory processes in dogs with AP.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36461714/